Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

More documents

Recommendations

Info

198 10° CONGRESSO NAZIONALE SIMIT Abstract 60 - TELBIVUDINA COME PROFILASSI ANTIVIRALE PER LA RECIDVIA DA HBV POST TRAPIANTO DI FEGATO: CASE REPORTS - Perrella A.* [1] , Lanza - Galeota A. [2] , Di Costanzo G. [2] , Pisaniello D. [2] , Marcos A. [2] , Migliaccio C. [2] , Calise F. [2] , Cuomo O. [2] - [1] AORN COtugno - AORN A. Cardarelli ~ nAPOLI - [2] Centro Trapianti Fegato AORN A Cardarelli ~ Napoli INFEZIONI DEL SISTEMA NERVOSO Premessa: La recidiva da HBV dopo Trapianto di fegato può rappresentare una condizione patologica pericolosa. Attualemnte la profilassi con immunoglobuline specifiche e lamivudina rappresenta il gold standard nella profilassi. Nonostante altri antivirali siano attiualemnte disponibili, pochi studi sono stati condotti sul loro possibile impiego e l‟impatto che possono avere sulla funzione renale nelle prime fasi del trapianto in questi soggetti Obiettivo: . Presentiamo in questa sede la nostra esperienza su 7 pazienti trapiantati per Cirrosi ed HCC HBV correlata e già in trattamento con Telbivudina 600mg/die mentre in lista di attesa per trapianto e successivamente trattati con lo stesso regime terapeutico come profilassi. In particolare abbiamo valutato l‟impatto precoce nei primi 3 mesi dopo trapianto sulla funzione renale, i livelli ematici di immunosoppressori, CPK, HBV-DNA, Transamiansis ai seguenti time points: T0 ( al momento del trapianto), T1 ( ad un mese), T3 (a tre mesi). Risultati: Tutti i pazienti sonpo stati trattati con un immunosoppressione basata su Inibitori Calcineurine. La CLearence della Creatinina (MDRD) a T0 era di 72,5 mL/min, 69,2 mL/min a T1 e 71 mL/min a T3. I livelli ematici di CPK non sono aumentati in corso di valutazione ne le transaminasi. Non sono stati riscontrati incrementi nei dosaggi ematici di inibitori delle calcineurine. L‟HBV-DNA è risultato negativo per tutto il periodo del follow-up Conclusione: La telbivudina come profilassi nei pazienti trapiantati per patologie terminali di fegato HBV correlate risultata essere efficace e sicura, senza influenza sulla funzionalità renale ed epatica. Altri studi sono richiesti su una coorte di pazienti più ampia per confermare questi dati.
199 10° CONGRESSO NAZIONALE SIMIT Abstract 58 - VARICELLA ZOSTER VIRUS INFECTION PRESENTING AS ISOLATED DIPLOPIA - Pisapia R.* [1] , Rianda A. [1] , Mariano A. [1] , Testa A. [1] , Oliva A. [1] , Abdeddaim A. [1] , Vincenzi L. [1] , Galgani S. [2] , Narciso P. [1] - [1] Istituto Nazionale per le Malattie Infettive "L. Spallanzani" ~ Roma - [2] UOD Day Hospital neurologico-neurochirurgico, Dip Neuroscienze. Ospedale San Camillo Forlanini. ~ Roma INFEZIONI DEL SISTEMA NERVOSO Premessa: Varicella Zoster Virus (VZV) causes central nervous system (CNS) complications, including isolated cranial nerve palsy. The etiological diagnosis of these cases may be challenging, because these manifestations can occur without the typical rash Obiettivo: A case of an immune-competent adult patient presenting diplopia as isolated symptom of CNS involvement of VZV infection is described for the first time, with the objective to stimulate the awareness of clinicians on VZV atypical presentations Risultati: A 33-years old male patient referred to our hospital because of diplopia occurring 6 hours before. He reported a self-limited episode of mild headache, myalgia and nausea without fever, occurred 7 days before. Neurological examination was unremarkable except for vertical and cross diplopia at left eye suggesting isolated fourth nerve palsy. Cerebro-spinal fluid (CSF) analysis evidenced pleocytosis, proteins 188 mg/dl and glucose 51 mg/dl with blood glucose of 111 mg/dl. In the suspicion of a viral encephalitis, acyclovir and anti-microbial therapy were started. As suggested by neurologist consultant, corticosteroids were added. Agents most frequently responsible of meningo-encephalitis resulted negative, as well as chest X-ray and MRI of the brain. Conversely, a PCR performed on CSF resulted positive for VZV-DNA, with a viral load of 30360 copies/ml. Acyclovir was continued up for 14 days. The diplopia progressively improved, and the patient was discharged after 21 days. He reported the complete disappearance of diplopia 45 days later Conclusione: VZV is now recognized as one of the main cause of adult encephalitis: in recent series, VZV has been identified as the second most common encephalitis cause. This case shows that clinicians should be aware of VZV role in CNS symptoms, even if the typical rash is lacking. The application of a standardized panel on CSF, including tests for most common agents causing neurological impairment, is useful
Page 1 and 2:
Abstract 230 - IMPIEGO DEI GLICOPEP
Page 3 and 4:
Abstract 223 - VANCOMICINA IN INFUS
Page 5 and 6:
5 10° CONGRESSO NAZIONALE SIMIT Ab
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
11 10° CONGRESSO NAZIONALE SIMIT A
Page 13 and 14:
Azithromycin R 2 Gentamicin S 1 Van
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Abstract 9 - SIEROPREVALENZA DELL
Page 29 and 30:
Page 31 and 32:
Abstract 170 - MALATTIA DI LYME A B
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Abstract 144 - EPIDEMIA DI TRICHINE
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
16 Legati al paziente 4 Non identif
Page 59 and 60:
Page 61 and 62:
Nausea 24 % Rinorrea 21 % Congiunti
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
75 10° CONGRESSO NAZIONALE SIMIT F
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Via di trasmissione TD vs altre 65.
Page 83 and 84:
Abstract 194 - LESIONE EPIGLOTTICA
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
101 10° CONGRESSO NAZIONALE SIMIT
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Genere maschile, n 30 (58%) Età me
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
TAS>51 TAS95%, n (%) 19 (61,3) 13 (
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148: 147 10° CONGRESSO NAZIONALE SIMIT
Page 161 and 162: Abstract 262 - SINDROME DI LYELL IN
Page 171 and 172: Abstract 117 - POTENZIALITÀ RIPROD
Page 173 and 174: Abstract 137 - INFEZIONI DA HBV, HC
Page 191 and 192: Demografiche Comorbidità Sintomi d
Page 193 and 194: Neisseria Meningitidis S. Pneumonia
Page 197: 197 10° CONGRESSO NAZIONALE SIMIT
Page 239 and 240: Abstract 55 - EPATITE VIRALE ACUTA
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
IL28b: CC HCVRNA UI/L, mediana (IQR
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Abstract 23 - UN CASO INUSUALE DI I
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
KIR2DL1 - HLA-C2 car 31/41 (75.6%)
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Abstract 305 - STREPTOCOCCAL SHOCK
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Study ID Greif (2000) Pryor (2004)
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Abstract 89 327 10° CONGRESSO NAZI
Page 329 and 330:
Page 331 and 332:
Abstract 72 - GRAVE QUADRO DI IRIS
Page 333 and 334:
show all

Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

Create successful ePaper yourself

Delete template?

Save as template?